Effects of Teriparatide in Postmenopausal Women With Osteoporosis

Lilly

Status and phase: Completed; Phase 4

Conditions: Postmenopausal Osteoporosis

Treatments: Drug: teriparatide; Drug: raloxifene; Drug: aldrenodate

Study type: Interventional

Funder types: Industry

Identifiers

NCT00079924

8141

B3D-MC-GHCM

Details and patient eligibility

About

Effects of Teriparatide in Postmenopausal Women Previously Treated with Alendronate or Raloxifene.

Sex: Female

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Postmenopausal women aged at least 50 years
• A previous clinical diagnosis of osteoporosis
• At high risk for fracture
• Current therapy for at least 18 months prior to study entry with either raloxifene HCl or alendronate Na

Exclusion criteria

• History of metabolic bone disease other than osteoporosis
• History of malignant neoplasm within the last 5 years except for superficial basal cell carcinoma or squamous cell carcinoma

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)